Concord Medical Services Holdings (FRA:C2C) Tariff Resilience Score: 5/10 (As of Jul. 05, 2026)


FRA:C2C Concord Medical Services Holdings Ltd FRA:C2C
51 GF Score
Price €6.25
GF Value €9.81
! 6 Warning Signs
View Full Analysis

What is Concord Medical Services Holdings Tariff Resilience Score?

Concord Medical Services Holdings FRA:C2C 51 Tariff Resilience Score is 5 as of Jul. 05, 2026. GuruFocus rates FRA:C2C with a GF Score™ of 51/100 and a GF Value™ of €9.81. The stock has 6 warning signs investors should review. Among 672 Healthcare Providers & Services companies, Concord Medical Services Holdings ranks better than 79.32% on this metric.

Concord Medical Services Holdings has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Concord Medical Services Holdings has Concord Medical's operations in China expose it to regional tariffs, but its focus on healthcare services rather than goods provides some insulation from direct tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Concord Medical Services Holdings might have Average Resilient.

Concord Medical Services Holdings  (FRA:C2C) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Concord Medical Services Holdings Tariff Resilience Score Related Terms

FRA:C2C vs CCEL, GBCS, CDIX: Tariff Resilience Score Comparison

For the Medical Care Facilities subindustry, Concord Medical Services Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Concord Medical Services Holdings Tariff Resilience Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Concord Medical Services Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Concord Medical Services Holdings's Tariff Resilience Score falls into.


FRA:C2C
51GF Score
Concord Medical Services Holdings Ltd FRA:C2C
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Concord Medical Services Holdings (FRA:C2C) has a Tariff Resilience Score of 5 as of Jul. 05, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Concord Medical Services Holdings ranks #139 out of 672 companies in the Healthcare Providers & Services industry, placing it in the top 20.7%.
Is Concord Medical Services Holdings' Tariff Resilience Score too high?
Concord Medical Services Holdings' current Tariff Resilience Score is 5. Based on the distribution chart, Concord Medical Services Holdings ranks #139 out of 672 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Concord Medical Services Holdings has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Concord Medical Services Holdings' Tariff Resilience Score compare to CCEL and GBCS?
According to the Healthcare Providers & Services industry distribution chart, Concord Medical Services Holdings ranks #139 out of 672 companies for Tariff Resilience Score. This places Concord Medical Services Holdings in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Healthcare Providers & Services company?
A good Tariff Resilience Score depends on the Healthcare Providers & Services industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Concord Medical Services Holdings's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Medical Services Holdings stock overvalued right now?
Concord Medical Services Holdings (FRA:C2C) has a current Tariff Resilience Score of 5. The stock's GF Value™ is €9.81, compared to a current price of €6.25 — trading 36.3% below its estimated fair value. The current Tariff Resilience Score is 5. Concord Medical Services Holdings' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Concord Medical Services Holdings (FRA:C2C), the current Tariff Resilience Score is 5 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Medical Services Holdings (FRA:C2C) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Medical Services Holdings stock appears to be undervalued. The current stock price of €6.25 is trading 36.3% below its estimated GF Value™ of €9.81.

Key valuation signals for FRA:C2C:

  • Tariff Resilience Score: 5
  • GF Value™: €9.81 vs. price of €6.25 (36.3% below fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the FRA:C2C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Medical Services Holdings Business Description

Other Exchanges CCM:USA
Address Hanwei Plaza Building, No. 7 Guanghua Road, Room A1-A5, 26th Floor, East Area, Chaoyang District, Beijing, CHN, 100020
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
51GF Score

Get the complete analysis for FRA:C2C

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.25
Price
€9.81
GF Value